Somatostatin Receptor Imaging in Acute Myocarditis and Cardiac Sarcoidosis
Key facts
- Who runs it
- Vastra Gotaland Region
- Where
- Sweden1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 78 people enrolled
- Started
- 20 Jan 2020
- Ended
- 24 Jun 2024
- Type of study
- Interventional, 2 groups
- Treatments tested
- 68Ga-DOTA-TOC PET/CT
- Blood sample
- Record updated
- 27 September 2024
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Willingness to participate in the study
- Provision of written informed consent
- All patients between the age of 18 and 85 of both genders
- Newly clinically suspected acute myocarditis or newly clinically suspected cardiac sarcoidosis with or without known extra-cardiac sarcoid
Who cannot take part
- Other known significant cardiac disease, including previous myocarditis
- Recent or current somatostatin analogue (octreotide) therapy
- Known tumour disease, especially (neuro)endocrine tumours
- Terminal disease(s), advanced psychiatric disease and/or significant dementia
- Pregnancy or lactation
- Severe obesity (limited by the scanner)
- Recent or current immunosuppressive treatment
- Known relative/absolute contraindications for contrast-enhanced MRI and/or PET/CT imaging
- Known contraindications for endomyocardial biopsy
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This prospective imaging study investigates the diagnostic ability of Gallium-68 DOTA-TOC (68Ga-DOTA-TOC) positron emission tomography/computed tomography (PET/CT) in the clinical work-up of patients with 1) clinically suspected acute myocarditis (n=30-40) and 2) clinically suspected cardiac sarcoidosis (n=30-40) using clinical diagnostic criteria as well as endomyocardial biopsy as reference. Furthermore, 68Ga-DOTA-TOC PET/CT findings will be compared with results from contrast-enhanced magnetic resonance imaging (MRI) and in case of cardiac sarcoidosis even Fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT, which are both performed as part of the clinical routine work-up.
The 2 groups in the trial
- Acute myocarditisTreatment being tested
Included patients with clinically suspected acute myocarditis (n=30-40) will undergo a 68Ga-DOTA-TOC PET/CT and a blood sample will be taken. Furthermore, participants will undergo a contrast-enhanced MRI and endomyocardial biopsy (if clinically indicated) as part of the clinical routine work-up.
Treatment: 68Ga-DOTA-TOC PET/CT and Blood sample
- Cardiac sarcoidosisTreatment being tested
Included patients with clinically suspected cardiac sarcoidosis (n=30-40) will undergo a 68Ga-DOTA-TOC PET/CT and a blood sample will be taken. Furthermore, participants will undergo a contrast-enhanced MRI, 18F-FDG PET/CT and endomyocardial biopsy as part of the clinical routine work-up.
Treatment: 68Ga-DOTA-TOC PET/CT and Blood sample
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Somatostatin Receptor Imaging in Inflammatory Heart Disease
- Record updated
- 27 September 2024